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Abstract
Background: Nasopharyngeal carcinoma (NPC) is common among Southern Chinese and the
main histology is the undifferentiated carcinoma associated with Epstein-Barr virus (EBV) infection.
p63 is a recently proved member of the p53 family based on the structural similarity to p53, but its
function in NPC is still unknown. This study was aimed to investigate the association between p63
and NPC.
Results: p63 was expressed in 100%(202/202) of nasopharyngeal carcinoma (NPC) tissues but not
in 29 nasopharynx inflammation and 17 non-cancerous nasopharyngeal epidermises on a tissue
microarray by immunohistostaining. Further investigation suggested that the p63 expression was
associated with the differential stage of NPC: p63 strong staining in Keratinizing squamous cell
carcinoma, differentiated non-keratinizing NPC and undifferentiated non-keratinizing NPC
presented the percentage of 5/8 (62.5%), 43/48 (92.5%) and 50/50 (100%), respectively. A significant
difference (p = 0.001) existed between the keratinizing and non-keratinizing groups. No pathogenic
mutations were detected in p63 gene in 12 primary NPC tissues and matched peripheral blood
lymphocytes (PBL). Half-life measurement study revealed distinct stability of p63 protein in the
different cell lines, especially between the carcinoma cell lines with EBV infection and the non-
cancerous cell lines. The results of immunoprecipitation suggested a direct interaction between
Epstein-Barr virus nuclear antigen 5 (EBNA-5) and p63 protein in NPC, and this binding would
increase the stability of p63.
Conclusion: Our data suggested p63 might be used as an adjunct diagnostic marker of NPC and
contributed a new way to understand the contribution of the EBV in the pathogenesis of NPC.
Background
Nasopharyngeal carcinoma (NPC) is an epithelial cancer,
the histology of which ranges from well-differentiated,
keratinizing squamous cell carcinoma to undifferentiated,
non-keratinizing carcinoma according to the World
Health Organization (WHO) histological classification of
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the tumors. The etiology of NPC is thought to be associ-
ated with genetic susceptibility, Epstein-Barr virus (EBV)
infection and some other environmental factors [1-5].
NPC has remarkable geographic and population differ-
ences in incidence. In the high incidence area – Southern
China, 90% of the NPC patients are undifferentiated, and
virtually all nonkerotinizing undifferentiated NPC are
associated with EBV [1,6,7].
The tumor suppressor gene p53 is mutated in more than
50% of human cancers [8] and 69% of human head and
neck squamous cell carcinomas(HNSCC) [9]; but it was
rarely mutate in NPC [10-13]. p63 was identified on the
basis of the structural similarity to the p53 tumor suppres-
sor protein. Differing from p53, the p63 gene generates
two major types of protein isoforms – TAp63 and ΔNp63
because of two promoters. TA isotypes contain a transac-
tivation domain homologous to that of p53 and can
mimic p53 transactivation function, whereas ΔN isotypes
lack this domain and block reporter activity mediated by
p53 and TA-p63 [14-16]. p63 is essential for regenerative
proliferation in limb, craniofacial and epithelial develop-
ment [17,18]. Over-expression of p63 was observed in
many human cancers, especially these less differentiated
tumors [19-24].
Epstein-Barr virus (EBV) is a ubiquitous human herpes-
virus associated with the development of both lymphoid
and epithelial tumors. [25-27]. Initial studies suggested
that it was involved in pathogenesis of NPC [2,4,28-30].
The Epstein-Barr virus nuclear antigen 5 (EBNA-5), highly
spliced mRNA from the major IR1 (BamHI-W) repeat
region of the virus genome, is proved to bind to p53 pro-
tein in Burk's lymphocyte [31,32]. The complex of the two
proteins can increase the accumulation of the p53 in the
nuclear.
Although p63 has high structural similarity according to
p53, they do not share similar function. The role of p63 in
NPC is still unclear. It was observed in this study that p63
was highly expressed in NPC and associated with the dif-
ferential stage of NPC. p63 gene took no mutation in
NPC, and nevertheless the stability of p63 protein in the
carcinoma cell lines was much higher than that in the
non-cancerous cell lines. The results of immunoprecipita-
tion demonstrated that p63 could interact with EBNA5 in
vivo, suggesting an important role in the EBV infection and
NPC development.
Materials and methods
Immunohistochemical assay
All tissue samples were obtained from the Sun Yat-sen
University Cancer center from 2000 to 2004. Immunohis-
tochemistry was performed on 202 undifferentiated NPC
samples, 29 nasopharynx inflammation and 17 non-can-
cerous nasopharyngeal epidermises on a tissue microar-
ray. Other 106 NPC tissue samples of different histologic
subtypes were used for further investigation. All the tissue
sections were stained with H&E and microscopically
examined to ensure the reliability of the diagnosis. Sec-
tions were deparaffinized and rehydrated through xylene
and alcohol. After incubated with 3% hydrogen peroxide
for 30 min at room temperature to block endogenous per-
oxidase, these sections were then rinsed in 0.01 M sodium
citrate buffer (pH 6.0) for 15 min at 95°C to unmask tis-
sue antigens. Immunostaining was performed with p63
4A4 (Santa Cruz) at 4°C overnight. The sections were
then developed according to the manufacturer's recom-
mendations (PV-9000 Polymer Detection System, Golden
Bridge International) and counterstained with haematox-
ylin. The evaluation of p63 expression was assessed semi-
quantitatively by staining intensity as negative, weak or
strongly positive according to Carcangiu's method [33].
These data were all assembled in double blind fashion by
two independent investigators without knowing the
patients' clinic pathological features and follow-up data.
Cell culture
C666-1 (a nasopharyngeal carcinoma cell line with EBV
infection), CNE-1 (a highly differentiated nasopharyngeal
carcinoma cell line), CNE-2 (a poorly differentiated
nasopharyngeal carcinoma cell line), HEK293 (a human
embryonic kidney cell line) and B95-8 (an EBV-positive
Burkitt's lymphoma cell line) were maintained in PRMI
1640 (GIBCO) supplemented with 10% fetal bovine
serum (Hyclone). NP69 (a nasopharyngeal epithelial
cells) was cultured by Keratinocyte-SFM (GIBCO) with
Bovine Pituitary Extract and rEGF. Cells were incubated
with 5% CO2 at 37°C.
PCR and DNA sequencing
Twelve primary NPC tissues and matched peripheral
blood lymphocytes (PBL) samples were used for p63
mutation analysis. The PCR products from NPC tissues
were firstly purified using the PCR purification Kit (Qia-
gen) and A-tailed. Then the A-tailed PCR products were
ligated into pGEM-T Easy vector (Promega) and propa-
gated in E.coli strain DH5α. At least 10 recombinant posi-
tive clones of each sample were sequenced. The PCR
products from matched PBL DNA were subjected to direct
sequencing. Both the sequencing results from NPC tissue
and PBL were analyzed by aligning to the p63 sequence
(Genebank:AB010153).
Measurement of p63 half-life
Cycloheximide (CHX) was added at 100 ug/ml and total
protein was isolated at 0, 1, 2, 4, 8, 16, 24 and 32 hour
after drug addition. The expression of p63 was quantita-
tively determined by Western blot and normalized by β-Journal of Translational Medicine 2006, 4:23 http://www.translational-medicine.com/content/4/1/23
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actin abundance. The half-life was calculated numerically
by using FORECAST (Excel).
Immunoprecipitation
Cells (3 × 107) were washed twice with ice-cold PBS and
dissolved in 200 ul of lysis buffer (20 mM HEPES pH 7.9,
100 mM NaCl, 1% NP-40, 0.5 mM EDTA, 0.5 mM PMSF).
Disrupted the cell lysate by sonication (10s on ice), spun
down cell extracts at 12000 rpm for 10 minutes at 4°C.
The immunoprecipitation were then performed according
to the Catch and Release v2.0 Kit (Catch and Release v2.0,
UPSTATE) recommendations. Lysates were incubated
with the anti-EBNA5 monoclonal antibody JF186 (a gift
from Karolinska Institute) at 4°C overnight on a rotator
by using a Catch and Release spin columns. Washed the
Column 3 times with 400 μl of 1X Wash Buffer, spinning
at 5000 rpm 15–30 seconds for each wash. Protein bound
to the beads was eluted by Denaturing Elution Buffer con-
taining 0.5% β-mercaptoethanol. Proteins were separated
by 10% SDS-PAGE, and then transferred to a PVDF mem-
brane (ROCHE). The membrane was incubated with p63
4A4 (Santa Cruz) at a 1:500 dilution. To further identify
this result, we also precipitated cell lysates with p634A4
and then did Western Blot with JF186. Western Blot was
done by using the Phototope-HRP Western Blot Detection
System kit according to the manufacturer's instructions
(Cell Signaling).
Statistical analysis
Data analysis was performed by using SPSS12.0 software
package. Pearson Chi-Square Test was used to test the
association between the p63 protein expression and the
differential stage of NPC. P < 0.05 was considered to be
statistically significant.
Results
Highly expression of p63 in NPC
All 202 undifferentiated NPC samples showed strong pos-
itive staining (Fig 1A), but 29 nasopharynx inflammation
(Fig 1C) and 17 non-cancerous nasopharyngeal epider-
mises (Fig 1D) were negative staining. The different
expression patterns of p63 staining in the tissue chip were
described in table 1. We also found p63 was highly
expressed in the cells with proliferative potential (Fig 1B)
and the shade of staining was correlated to cell differenti-
ation potency. In addition, recent studies revealed that
p63 is highly expressed in the basal and suprabasal epithe-
lium [34]. Totally, our data demonstrated the expression
pattern of p63 was remarkably different between non-can-
cerous nasopharyngeal and NPC and revealed that p63
could be used as a valuable diagnostic marker in clinical
adjuvant diagnosis of NPC.
The expression of p63 is associated with the differential 
stage of NPC
To further investigate the relationship between the p63
expression and the differential stage of NPC, we analyzed
106 NPC tissue samples of different histological subtypes,
containing 50 undifferentiated carcinomas, 48 differenti-
ated carcinomas and 8 keratinizing squamous cell carci-
nomas. The different expression patterns of p63 in
different differential stage NPC were displayed in figure 2.
All the tissue samples showed nucleus staining, while the
intensity of the staining was different with the degree of
malignant (Table 2). A significant difference (p = 0.001)
existed between the keratinizing and non-keratinizing
groups. As the keratinizing squamous cell carcinomas was
very rarely in the NPC patients of Southern China, we
only collected 8 samples in Sun Yat-sen University Cancer
center from 2000 to 2004. Although the sample number
was few, it indicated a tendency of weak p63 expression in
the Keratinizing squamous cell carcinoma. Our data sug-
gested the expression of p63 protein was associated with
the differential stage of NPC.
Mutation analysis of p63 in NPC
Fourteen exons of p63 were amplified and examined in 12
primary NPC tissues and matched PBL samples. Since
NPC tissues are confounding with large number of infil-
trating lymphocytes, direct sequencing of PCR products
may not reveal the real mutation status. We used the PCR-
cloning sequencing strategy to ensure the purity of the car-
cinoma cells. Our study indicated the same results to
other studies. Unlike p53, p63 mutation was uncom-
monly found in human cancer cell lines and tumors [35-
37], although it was strongly associated with the develop-
ment abnormality diseases [17,18,38]. The results sug-
gested that p63 gene mutation was not responsible for the
high expression of p63 protein.
The expression of p63 is associated with its stability
Stability of p63 in the different cell lines was shown in Fig-
ure 3. A time course using cycloheximide at 100 ug/ml
was used to obtain an accurate determination of the half-
life of p63 and demonstrated differences in the degrada-
tion of p63 in different cell lines. The expression of p63
was quantitatively determined by Western blot and nor-
malized by β-actin abundance. The half-life of p63 in dif-
ferent cell lines was described in Figure 4. The interaction
of p53 with other proteins is known to alter the stability
of p53. In this study, we found the half-life of p63 in the
carcinoma cell lines was clearly longer than non-carci-
noma cell lines, especially the carcinoma cell lines with
EBV infection.
Direct interactions between p63 and EBNA-5
To further identity the molecular mechanism of high
expression of p63, we performed co-immunoprecipita-Journal of Translational Medicine 2006, 4:23 http://www.translational-medicine.com/content/4/1/23
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tion with p63 and EBNA5. The protein complex of p63
and EBNA-5 were tested in both the C666 cell line and
B95-8 cell line, and NP69 was used as a negative control
(Fig 3). Like p53, p63 was rarely mutated but take high
expression in NPC. High expression of p53 was indicated
in inactive form due to the binding with EBNA5 in Burk's
lymphocyte [31,32], and the complex of the two proteins
led to increased accumulation of p53 in nuclei. p63 have
a high amino acid identity to p53. Our study also revealed
that the interaction between p63 and EBNA5 might con-
tribute for the stability of p63.
Discussion
Despite structural and functional similarities between p63
and p53, there are many differences. Inactivation of wild
type p53 is indicated in most human cancers due to muta-
Table 1: Expression of p63 immunohistochemical staining in the tissue chip
Nasopharyngeal carcinoma n = 202 strong positive staining
Nasopharynx inflammation n = 29 negative staining
Non-cancerous nasopharyngeal epidermis n = 17 negative staining
Immunohistochemical demonstration of p63 protein expression Figure 1
Immunohistochemical demonstration of p63 protein expression. Strong positive staining of p63 protein in NPC(A) 
and the basal layer cells with proliferate potential(B); negative staining of p63 protein in nasopharynx inflammation (C) and non-
cancerous nasopharyngeal epidermises(D). (All the photomicrographs were taken in high-powered, ×400).Journal of Translational Medicine 2006, 4:23 http://www.translational-medicine.com/content/4/1/23
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tion or interaction of other protein. Previous studies dem-
onstrated that some viral proteins could bind to p53, to
prevent its degradation and accumulate in the cell nuclear,
and results in high expression. In this study, we found that
p63 is highly expressed in NPC, especially the histology of
undifferentiated. Considering no mutation detected in
NPC, we concluded that gene mutation was not responsi-
ble for the high expression of p63 in NPC. p53 protein is
labile and its activity is regulated by its degradation and its
level of stability. p53 levels are controlled largely by
Mdm2. Mdm2 can also bind with p63, but Mdm2 are not
able to repress p63-induced transcription or to affect its
Immunohistochemical demonstration of p63 protein expression in different histology NPC Figure 2
Immunohistochemical demonstration of p63 protein expression in different histology NPC. Strong nuclear stain-
ing of p63 in keratinizing NPC (A) differentiated non-keratinizing NPC (B) and undifferentiated non-keratinizing NPC (C)(All 
the photomicrographs were taken in high-powered, ×400). The staining intensity is associated with the differential stage of 
NPC.
Table 2: Expression pattern of p63 in 106 NPC samples with different differentiation status
Differentiated status Weak staining Strong staining
Keratinizing squamous cell carcinoma n = 8 3 (37.5%) 5 (62.5%)
Differentiated non-keratinizing NPC n = 48 5 (7.5%) 43 (92.5%)
Undifferentiated non-keratinizing NPC n = 50 0 (0%) 50 (100%)
(x2 = 14.934, df = 2, p = 0.001)Journal of Translational Medicine 2006, 4:23 http://www.translational-medicine.com/content/4/1/23
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half-life [39]. In addition, other researchers found that
Mdm2 helped increase transcriptional activity and the
protein level of p63 [40]. The regulation of the stability of
p63 is complex and still poorly understood. Our study
suggested a distinct difference of half-life between the car-
cinoma cell lines with EBV infection and the non-cancer-
ous cell lines. And we found that there is a directly
interaction between the EBNA-5 and the p63 protein in
NPC by taking the co-immunopreciatiate experiment.
These results suggested the interaction with the virally
encoded protein might contribute to increase the stability
of p63. Although the expression pattern of the p63 is
researched generally, the mechanism of its high expres-
sion remains an enigma. Therefore, our research was pro-
viding a novel mechanism for the degradation of p63.
The role of p63 in tumorigenesis is complex. p53 was
firstly heralded as an oncogene because of its potent trans-
formation capabilities and its robust expression in human
tumors. However, it was later discovered that only mutant
p53 was oncogenic, and that wild type p53 was a tumor
suppress gene. Differing from p53, p63 was rarely
mutated or inactivated in human cancers, and p63 null
mice failed to develop tumors [17,18,37]. Our results
showed that the p63 protein was highly expressed in NPC
and associated with its differential stage, suggesting it to
be a valuable diagnostic marker. In South China, the area
with high incidence of NPC, 90% of the NPC patients are
undifferentiated, and nonkerotinizing undifferentiated
NPC are all associated with EBV [1,6,7]. NPC is unique in
that the exogenous EBV is present exclusively in the cancer
cells, but not in the surrounding normal tissues, providing
Co-immunoprecipitation of p63 and EBNA-5 Figure 5
Co-immunoprecipitation of p63 and EBNA-5. (A) Cell 
extract were precipitated with the JF186 and analysed by 
Western blot with p63. (B) Cell extract were precipitated 
with the p63 and analysed by Western blot with JF186.
Stability of p63 with CHX treatment Figure 3
Stability of p63 with CHX treatment. CHX was added 
at 100 ug/ml and total protein was extracted as indicated. 
Western blots were performed with p63 and β-actin in (A) 
B95-8 cells, (B) C666 cells, (C) CNE2 cells, (D) CNE1 cells, 
(E) NP69 cells, (F) 293 cells.
Half-life of p63 in the different cell lines Figure 4
Half-life of p63 in the different cell lines. The half life of 
p63 was 38.64h, 36.42h, 27.47h, 19.74h, 9.76h, 6.93h accord-
ingly to B95-8cells, C666 cells, CNE2 cells, CNE1 cells, NP69 
cells and 293 cells respectively.Journal of Translational Medicine 2006, 4:23 http://www.translational-medicine.com/content/4/1/23
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an obvious exploitable opportunity [41]. The expression
of p63 takes a completely identity of the presentation of
EBV. p63 is highly expressed in the carcinoma cells but
not in the normal tissues. This is strong evidence to dem-
onstrate the association between the p63 and EBV.
EBV plays an etiological role in the development of NPC.
However, how EBV contributes to NPC formation has not
been clearly elucidated. Our results proved that the inter-
action of p63 and EBNA5 in vivo. EBNA-5 was required for
B-cell transformation [42] and efficient outgrowth of lym-
phoblastoid cell lines (LCLs) [43]. Previous studies sug-
gested that it was mainly co-operated with EBNA-2 [44].
EBNA2 can transactivating the latent membrane protein 1
of EBV (LMP1) [45]. Numerous studies have revealed the
oncogenic properties of LMP1, including increasing cell
proliferation and invasion; inhibiting apoptosis, senes-
cence and differentiation [46-49]. LMP1 is conformed as
EBV oncogene in NPC [50,51]. We think the p63 may
impose an impact on LMP1 by interaction with EBNA2.
But how they exert the effect and what are the detailed
mechanisms making them to function are still waiting to
be discovered.
Totally, our study identified a high expression of p63 in
NPC cells and the level of p63 expression was correlated
with the differential stage of NPC, suggested p63 might be
used as an adjunct diagnostic marker of NPC. And the
interaction between p63 and EBNA5 might contribute for
the stability of p63. These results implied an important
role of p63 gene in development of NPC and prompted a
new way to understand the contribution of the EBV in the
pathogenesis of NPC.
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